drug

Barry Massie Barry Massie, San Francisco VA Medical Center COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment a

Silvia Novello SILVIA NOVELLO, University of Turin Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello w

Volume 16 Number 6 (March 15th, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) American Society of Hematology Annual Meeting (December 8-11, 2007

Bart Barlogie Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 BART BARLOGIE, University of Arkansas, Little Rock A treatment known as “total therapy

David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine

Peter Tyrer REFERENCE: Lancet 371:57 January 5, 2008 PETER TYRER, Imperial College, W6 8RP London A randomized study comparing treatment with risperidone, or haloperidol, or placebo to treat patients

Jose Baselga JOSE BASELGA, Vall d’Hebron Hospital, Barcelona RAD001, a drug targeted at the mTor pathway, has been combined with letrozole in a randomised phase II trial in breast cancer. The in

Terry Gernsheimer TERRY GERNSHEIMER, University of Washington Medical Center, Seattle An investigational drug AMG 531 has increased and sustained platelet counts in splenectomized patients with chroni

Laura Mauri Raymond Gibbons REFERENCE: Late Breaking Special Session, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LAURA MAURI, Brigham and Woman’s Hospit

REFERENCE: Abstract: Late Breaking Clinical Trials, Session 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida LESLEE SHAW, Emory University, Atlanta COMMENT: DANI

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

Daniel Diekema, University of Iowa, Iowa City A large, global survey of candida distribution and drug susceptibility reported at the ICAAC found that fluconazole resistance among candida glabrata appe

Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that two drugs are better than one; and three are better than two, this h

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH